Skip to main content
OpenTrials
Completed

NCT Number: NCT02816580

Biological MArkers of FRAilty in Elderly Subjects

Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency.

On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Elderly Persons

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chu de Reims

Reims, 51092, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • With social security coverage
  • Accept to participate in the study and sign informed consent for the study and for the collection of biological samples

Exclusion criteria

  • < 65 yo

Treatment and study plan

Blood collection

Other

Primary outcomes

  1. post-translational modification derived-products (PTMDP) quantification by Multidimensional Chromatography Coupled withTandem Mass Spectrometry (LC/LC-MS/MS)

    Time frame: baseline

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects

Acronym: MAFRA

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jun 28, 2016
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.